Leading the way.

PRESIDENT & CEO

Mr. Fallon is President, CEO and co-Founder of Promontory Therapeutics. He is a highly respected leader with decades of global transactional and strategic leadership. He is former Chairman & CEO of The Korea Exchange Bank, a large publicly traded company, and prior to that he ran all of Asia-Pacific for JP Morgan Chase.

He holds a BA in Mathematics from Ohio University, and an MBA from Harvard Business School.

Mr. Fallon has previously served as Director of the Japan Society, the Korea Society, Trustee of the Ohio University Foundation, Chairman of the Council on International Educational Exchange and a Professional Fellow of the Center on Japanese Economy and Business of Columbia University. He also served on the Advisory Board of the Korea Economic Institute and the Asian Advisory Boards of Deutsche Bank AG and Euromoney PLC. He is a member of Asia Society in NY, the Council on Foreign Relations and the Woods Hole Oceanographic Institution Corporation.

EXECUTIVE VICE PRESIDENT & COO

Mr. Price is Executive VP, Chief Operating Officer and co-Founder of Promontory Therapeutics, and has been responsible for strategy and operations across the company's activities since inception. He was named an Emerging Pharma Leader by Pharmaceutical Executive magazine in 2022, and the only company co-founder. He represented the company as a Prix Galien Best Startup Nominee in 2023.

Mr. Price helped negotiate the original license for the company's PT-112 development program, and helps to oversee clinical and translational research and development, manufacturing and external relations. He was responsible for the company's clinical trials collaboration jointly with Pfizer and Merck KGaA, Darmstadt, Germany, leads its relationship under a formal CRADA with the National Cancer Institute (NCI), and serves as the U.S. regulatory agent with FDA.

He previously held research and managerial roles in the NGO and non-profit sectors working in the US and Germany. He holds an AB from Princeton University, graduating summa cum laude and Phi Beta Kappa, and earned his MBA from Columbia Business School as a Chazen Society Fellow in International Business.

His resulting focus was on mission-driven entrepreneurship, whereby he found his home in biotech and oncology drug development. He is a frequent contributor to industry panel discussions and podcasts, and is a member of ASCO and ESMO.

EXECUTIVE VICE PRESIDENT & CMO

Dr. Johan Baeck is an experienced industry clinician with deep expertise in oncology clinical development. Dr Baeck’s focus over the last years has been on the development of novel therapeutic approaches in oncology, specializing in small molecules, immunotherapy and biologic agents for the treatment of solid tumors and hematologic malignancies.

Prior to joining Promontory Therapeutics, Dr. Baeck served as Senior Vice President of Clinical Development and Medical Affairs at Jounce Therapeutics.

Dr. Baeck’s extensive clinical development and medical affairs experience encompasses both early and late phase programs. Product and program focus has been on ribociclib (Kisqali®, HR+, HER2- metastatic breast cancer) and ceritinib (Zikadia®, ALK-positive NSCLC) while at Novartis; azacitidine (Vidaza®, myelodysplastic syndrome) while at Pharmion; leuprolide (Lupron®, prostate cancer) while at Abbott; vopratilimab (NSCLC), pimivalimab (PD-1 inhibitor), JTX-8064 (LIRB-2 inhibitor) and JTX-1811 (CCR-8 inhibitor) while at Jounce Therapeutics.

Dr. Baeck completed his Medical Degree in Leuven, Belgium and was a practicing physician in Belgium before transitioning to the pharmaceutical industry.

SVP, RESEARCH & DEVELOPMENT

Dr. Ames is Senior Vice President of Research & Development at Promontory Therapeutics, and leads the company's translational research efforts globally across multiple institutions.

He coordinates numerous collaborations with partners across academia, industry, and government to deepen insights into the safety, efficacy, and mechanism of action of Promontory's therapeutic programs, ultimately accelerating the path to patients. Dr. Ames is a co-inventor on two of Promontory's key patent portfolios and has been published in journals such as OncoImmunology, The Lancet’s eClinicalMedicine, Cancers, Nature Chemical Biology, Nature Structural and Molecular Biology, and the Journal of Translational Medicine.

Dr. Ames received his BS with high distinction in Biology and Biotechnology from Worcester Polytechnic Institute and earned his doctorate in Molecular, Cellular and Developmental Biology from Yale University, where he focused on nucleic acid biochemistry in the lab of Ronald Breaker, PhD.

Prior to joining Promontory, he was a post-doctoral fellow at the University of California Berkeley, concentrating on the commercial applications of yeast genetics.

SENIOR MEDICAL DIRECTOR

Dr. O’Donnell is Senior Medical Director at Promontory. He focuses on patient eligibility, enrollment and clinical case managements.

Dr. O’Donnell comes to the Company from the Geisel School of Medicine at Dartmouth, where he was an Associate Dean at the medical school and senior scholar at the C. Everett Koop Institute, and held the Elizabeth DeCamp McInerney endowed chair as a Professor of Medicine and Psychiatry. He was chief of oncology at the Dartmouth affiliated White River Junction VA Hospital, and a member and former associate director of the Norris Cotton Cancer Center. He has had extensive experience in clinical oncology, especially involving the cancers of most interest to Promontory Therapeutics, and has extensive clinical trials experience with CALGB, RTOG, VA Cooperative Studies and locally initiated Dartmouth protocols. He is past president of the American Association for Cancer Education, past editor of its Journal of Cancer Education and recipient of its highest award, the Margaret Hay Edwards Medal for achievement in cancer education. Dr. O’Donnell previously served on the Company’s Scientific Advisory Board since inception.

He graduated with an A.B. in biology summa cum laude from Harvard College and an MD from Harvard Medical School. He did his internal medicine training at Dartmouth and his oncology training as a clinical associate at the National Cancer Institute. He is board certified in Internal Medicine and Medical Oncology. Dr. O’Donnell is a former member of the board of Harvard Pilgrim HealthCare, the second largest insurer in New England.

VP, CHEMISTRY MANUFACTURING & CONTROLS

Dr. Shea is Vice President of Chemistry, Manufacturing and Controls (CMC) and is responsible for all technical operations including manufacturing, analytical development and supply chain. Throughout her career, she has held a number of roles of increasing leadership responsibilities at both small and large companies including Head of CMC at AMAG Pharmaceuticals and the Head of the Catalysis Laboratory at Johnson Matthey Pharma Services. Her oncology experience includes her drug substance program leadership for brigatinib (Alunbrig ®) at Ariad Pharmaceuticals. Prior to joining Promontory, she was VP, Head of CMC at Saniona, a Danish rare disease company.

Dr. Shea graduated with a BA in Chemistry from the College of the Holy Cross and a PhD in Organic Chemistry from Dartmouth College, and held a post-doctoral fellowship at Texas A&M University.

DIRECTOR, REGULATORY AFFAIRS

Ms.Chaudhry is Senior Director, Regulatory Affairs at Promontory Therapeutics, and has been responsible for pharmacovigilance and drug safety reporting. She has managed global submissions to regulatory authorities and developmental partners, overseeing quality control, and has significant experience working with investigators and clinical research staff to ensure subject safety during the conduct of clinical trials. Additionally, she coordinates regulatory strategy with external expert advisors.

Ms.Chaudhry has held clinical research and pharmacovigilance roles at institutions such as Rutgers Cancer Institute of New Jersey, and at pharmaceutical companies including Eisai and Otsuka. She holds a B.S in Biology from the University of Maryland, Baltimore County and earned her Masters in Regulatory Sciences from the University of Maryland, School of Pharmacy.

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for HonorHealth Clinical Research Institute and Medical Director of Research at McKesson Specialty Health, US Oncology Research. He is also Professor of Medicine, Mayo Clinic Scottsdale, AZ.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and others. His clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 675 papers, 140 book chapters and over 1170 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was also a Founder of Ilex Oncology, which obtained FDA approval for two new anti-cancer agents: Campath for the treatment of patients with CLL and multiple sclerosis; and Clofarabine for the treatment of children with Leukemia. The company was acquired by Genzyme.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Dr. Karp graduated from Harvard College in 1969, and received his medical degree from the Duke University School of Medicine in 1973. He was awarded numerous postgraduate and clinical fellowships, including at the Sidney Farber Cancer Institute in Boston from 1978-80. Dr. Karp’s focus at MD Anderson Cancer Center is on new drug development in the phase I facility, as well as medical graphics and informatics, and cancer chemoprevention.

Dr. Karp is proud to have had a role in the early clinical trials of Epirubicin, the Taxanes, and the new Targeted Oral Inhibitors of the Epidermal and Vascular Growth Factor Receptors, as well as in recent studies of the Insulin Growth Factor Receptor (IGFR).

Dr. Galluzzi is a world-renowned scientist who has been honored as one of the most highly cited researchers in the field of Immunology, Molecular Biology and Genetics, with over 500 publications. His pioneering research included the seminal characterization of immunogenic cancer cell death (ICD) and the adaptive immune response. Dr. Galluzzi holds multiple professorial roles, including at Weill Cornell Medical College as head of the Galluzzi Lab and Assistant Professor of Cell Biology in Radiation Oncology, and at Yale School of Medicine as Assistant Professor Adjunct, and a faculty appointment at University of Rome “La Sapienza”. He is also an associate director of the European Academy for Tumor Immunology, and founding member of the European Research Institute for Integrated Cellular Pathology. Dr. Galuzzi completed his post-doctoral training at the Gustave Roussy Comprehensive Cancer Center in France, after receiving his PhD from the University Paris Sud.

Dr. Noel has had thirty years of experience in pharmaceutical drug development. She currently serves as Chief Operating Officer of Collaborative Medicinal Development, a privately held drug development group focused on neuro-degenerative diseases. She was previously Co-founder and COO of OncoEthix SA, which was sold to Merck in 2014, and before that was Co-Founder and VP of Business Development of Oncology Therapeutics Network, which was sold to Bristol Myers Squibb.

Earlier in her career she was director of Biologics R&D at Abbott. Dr. Noel holds a PhD in Biophysics from the University of Michigan, and completed post-doctoral studies at UCLA under a fellowship from the National Institutes of Health.

Dr. Jimeno is a seasoned medical oncologist, who also holds a PhD from the University of Barcelona. He has had a focus in drug development for over twenty years. Dr. Jimeno served as Chief Medical Officer at Promontory Therapeutics, in which role he was instrumental in the early clinical development of PT-112, and joins the Scientific Advisory Board in order to maintain his involvement in the program. He was formerly VP of Clinical and Scientific Development at PharmaMar, responsible for the integrated development of Yondelis®, which is approved in the US, the EU, Japan, and more than 60 other countries for the treatment of ovarian cancer and sarcoma; the development of Aplidine® in advanced cancer patients; and the design of the pivotal study in multiple myeloma, which has had its first approval in Australia.

His prior industry roles include work at Farmitalia Carlo Erba and US Biosciences, where he focused on novel compounds in the anthracycline and anti-metabolite therapeutic classes. Most recently, Dr Jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company focused on personalized medicine, where he was involved in the development of the EGFR mutation diagnostic approved by the FDA for use in non-small cell lung cancer (NSCLC) cancer patients. Dr. Jimeno has published over 100 papers in peer review journals on cancer and is a guest lecturer in immunology at The University of Zaragoza in Spain.

Dr. Scher, D. Wayne Calloway Chair in Urologic Oncology, has dedicated his career to the co-development of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to assess treatment efficacy, guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. During his 25-year tenure as the Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) he led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of the disease, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved.

In his current roles—Head of MSKCC’s Biomarker Development Program; Member and Attending Physician, Genitourinary Oncology Service, Department of Medicine at MSKCC; and Professor of Medicine at the Weill Cornell Medical College—Dr. Scher applies the same principles used in developing drugs to blood and imaging-based biomarkers in a regulatory context to better inform diagnostic and therapeutic decisions so that patient outcomes are improved.

Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence (SPORE) in Prostate Cancer at MSKCC and the Department of Defense-sponsored Prostate Cancer Clinical Trials Consortium (PCCTC), and has received the 2015 AACR Team Science Award for his multidisciplinary work developing AR inhibitors, the Donald S. Coffey-Prostate Cancer Foundation Physician Scientist award and the Chemotherapy Foundation Ezra Greenspan Award. Dr. Scher was elected to the Association of American Physicians and named a Fellow of the American Society of Clinical Oncology (ASCO).